11C-ER176 for Alzheimer's Disease

Phase-Based Progress Estimates
Columbia University Irving Medical Center, New York, NYAlzheimer's Disease11C-ER176 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is looking at whether a gene variant affects microglial activation and TSPO binding in Alzheimer's disease, and if so, what the consequences are.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Up to 1 year

Up to 1 year
Correlation between the chromosome 1 variant (rs2997325) and TSPO binding
Number of variants discovered in genome-wide association study (GWAS) that influence TSPO binding

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

Trial Design

2 Treatment Groups

No Cognitive Impairment
1 of 2
Cognitive Impairment
1 of 2

Active Control

Experimental Treatment

250 Total Participants · 2 Treatment Groups

Primary Treatment: 11C-ER176 · No Placebo Group · Phase 2

Cognitive ImpairmentExperimental Group · 2 Interventions: 18F-florbetaben, 11C-ER176 · Intervention Types: Drug, Drug
No Cognitive ImpairmentActiveComparator Group · 2 Interventions: 18F-florbetaben, 11C-ER176 · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year

Who is running the clinical trial?

William Charles KreislLead Sponsor
6 Previous Clinical Trials
306 Total Patients Enrolled
Edward D Huey, MDLead Sponsor
National Institute on Aging (NIA)NIH
1,442 Previous Clinical Trials
4,246,526 Total Patients Enrolled
William Kreisl, MDPrincipal InvestigatorColumbia University
2 Previous Clinical Trials
80 Total Patients Enrolled
Edward Huey, MDPrincipal InvestigatorColumbia University
3 Previous Clinical Trials
52 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

What safety measures should be taken when administering 11C-ER176?

"We have rated 11C-ER176 a 2 on our safety scale, as Phase 2 trials typically provide evidence for the former but not the latter." - Anonymous Online Contributor

Unverified Answer

How many people can participate in this research endeavor?

"Affirmative. According to clinicaltrials.gov, this research study posted on May 11th 2021 is currently recruiting participants. There are 250 spots at a single site for potential patients who meet the criteria." - Anonymous Online Contributor

Unverified Answer

Is enrollment open to new participants in this research protocol?

"Per clinicaltrials.gov, this medical research is still in need of participants. It was made public on May 11th 2021 and underwent its most recent update on September 15th 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.